,,iii #aaith ,,congress #b;d ,session ,s4 ,,res4 #fbj ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,february #bf1 #bjbf,mr4 ,barrasso 7for himself and ,mr4 ,blumenthal7 submitted the following resolution2 which was considered and agreed to ,,resolution ,designating ,february #bh1 #bjbf1 as ,rare ,disease ,day4 ,whereas a rare disease or disorder is a disease or disorder that affects a small number of patients2 ,whereas1 in the ,united ,states1 a rare disease or disorder is defined as affecting fewer than #bjj1jjj individuals2 ,whereas1 as of the date of adoption of this resolution1 more than #cj1jjj1jjj individuals in the ,united ,states are living with at least #a of the more than #aj1jjj known rare diseases or disorders2 ,whereas children with rare diseases or disorders account for a significant portion of the population affected by rare diseases or disorders in the ,united ,states2 ,whereas many rare diseases and disorders are serious and life-threatening2 ,whereas financing life-altering and lifesaving treatments can be challenging for individuals with a rare disease or disorder and their families2 ,whereas individuals with rare diseases or disorders can experience difficulty in obtaining accurate diagnoses and finding physicians or treatment centers with expertise in their rare disease or disorder2 ,whereas1 although there have been great advancements in finding treatments for rare diseases1 approximately #ie percent of rare diseases still do not have a treatment approved by the ,,fda2 ,whereas #bjbf marks the #dcrd anniversary of the enactment of the ,orphan ,drug ,act 7,public ,law #ig-dad2 #if ,stat4 #bjdi71 a landmark law enabling tremendous advances in the research and treatment of rare diseases and disorders2 ,whereas the ,national ,institutes of ,health support innovative research on the treatment of rare diseases and disorders2 ,whereas programs such as the ,accelerating ,rare disease ,cures ,program of the ,food and ,drug ,administration 7referred to in this preamble as the ,,fda7 aim to drive scientific and regulatory innovation and engagement to accelerate the availability of treatments for patients with rare diseases2 ,whereas #bc of the #df novel drugs approved by the ,center for ,drug ,evaluation and ,research of the ,,fda in #bjbe-- 7#a7 were approved to prevent1 diagnose1 or treat a rare disease or condition2 and 7#b7 received an orphan-drug designation2 ,whereas ,rare ,disease ,day is observed each year on the last day of ,february2 and ,whereas ,rare ,disease ,day is a global event that was first observed in the ,united ,states on ,february #bh1 #bjji3 ,now1 therefore1 be it ,that the ,senate-- 7#a7 designates ,february #bh1 #bjbf1 as ,rare ,disease ,day2 and 7#b7 recognizes the importance of1 with respect to rare diseases and disorders-- 7,a7 improving awareness2 7,b7 encouraging accurate and early diagnosis2 and 7,c7 supporting national and global research efforts to develop effective treatments1 diagnostics1 and cures4